학술논문

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.
Document Type
Article
Source
Emerging Microbes & Infections; Dec2022, Vol. 11 Issue 1, p1910-1919, 10p
Subject
Language
ISSN
22221751